Month: November 2022

On September 30, 1976, Yutilov, Yu. M.; Svertilova, I. A. published an article.Computed Properties of 41010-50-8 The title of the article was New method for preparing condensed imidazolones. And the article contained the following:

Imidazoles I and II (X = CH, N; R = H, Cl; R1 = H, Me, Et, R2 = H, Me, Ph, CH2Ph) were obtained in 80-99% yields by treatment of the corresponding o-phenylenediamine or diaminopyridine with EtO2COCO2Et. The experimental process involved the reaction of 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one(cas: 41010-50-8).Computed Properties of 41010-50-8

The Article related to cyclocondensation phenylenediamine pyrocarbonate, pyridinediamine cyclocondensation polycarbonate, imidazolone condensed, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Computed Properties of 41010-50-8

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On March 16, 2018, Delsarte, Christine; Santraine, Romuald; Fours, Baptiste; Petit, Laurent published an article.Name: 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole The title of the article was Metal-Free Synthesis of the Methanol Solvate of (S)-Omeprazole Potassium Salt Using (1R)-(-)-10-Camphorsulfonyloxaziridine: Oxidation Process Development and Optical Purity Enhancement Strategy. And the article contained the following:

The results of our process development studies to synthesize the methanol solvate of (S)-omeprazole potassium salt through the enantioselective oxidation of pyrmetazole using (1R)-(-)-10-camphorsulfonyloxaziridine are reported. Optical purity enhancement was achieved by means of a reslurry from methanol, the rationale and development details of which are also described. The experimental process involved the reaction of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole(cas: 73590-85-9).Name: 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole

The Article related to pyrmetazole camphorsulfonyloxaziridine enantioselective oxidation, omeprazole potassium salt stereoselective preparation, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Name: 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On March 31, 2016, Song, Guo-Qiang; Qin, Feng; Huang, Xian-Feng; Lv, Xiao-Bing; Yang, Bei published an article.Electric Literature of 73590-85-9 The title of the article was Easy Removal of N-carboxybenzyl (Cbz) Protective Group by Low-Carbon Alcohol. And the article contained the following:

A new method for the removal of benzyloxycarbonyl protective group was established. It was accomplished by using methanol, ethanol or t-butanol as a deprotective reagent, and the scope and limitations of this method were also preliminarily investigated. These results broadened utility of N-Cbz protective group in synthetic chem., especially in synthesis or use of imidazole, benzimidazole, pyrazole or their derivatives The experimental process involved the reaction of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole(cas: 73590-85-9).Electric Literature of 73590-85-9

The Article related to imidazole pyrazole benzimidazole preparation, pyrazole imidazole benzimidazole benzyloxycarbonyl deprotection low carbon alc, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Electric Literature of 73590-85-9

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On May 5, 2022, Slassi, Siham; Aarjane, Mohammed; Amine, Amina published an article.Synthetic Route of 5036-48-6 The title of the article was Synthesis, spectroscopic characterization (FT-IR, NMR, UV-Vis), DFT study, antibacterial and antioxidant in-vitro investigations of 4,6-bis((E)-1-((3-(1H-imidazol-1-yl)propyl)imino)ethyl)benzene-1,3-diol. And the article contained the following:

A new bis-Schiff base, I derived from N-(3-aminopropyl)imidazole and 4,6-diacetylresorcinol was obtained. The bis Schiff base I was characterized through mass spectrometry, elemental anal., IR, UV-Vis, 1H and 13C NMR spectroscopy. The B3LYP method was used to calculate the optimized structure of the mol. through d. functional of theory (DFT) using the 6-31G (d, p) basis set. The 1H and 13C NMR chem. shifts with respect to TMS were calculated using the (GIAO) method in DMSO-d6 and compared with the exptl. data. In addition, the frontier MOs, electronic properties and the mol. electrostatic potential (MEP) of RS were investigated using DFT calculations The compound showed significant antibacterial activity against Staphylococcus aureus. The DPPH free radical scavenging assay was used to evaluate the antioxidant activity. The effective concentration (EC50) showed that the compound has a good antioxidant activity. The experimental process involved the reaction of N-(3-Aminopropyl)-imidazole(cas: 5036-48-6).Synthetic Route of 5036-48-6

The Article related to bis imidazolyl propyl imino ethyl benzenediol preparation schiff base, antibacterial antioxidant surface electrostatic potential, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Synthetic Route of 5036-48-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On March 6, 1973, Robison, Michael Mullen; Finch, Neville published a patent.Product Details of 41010-50-8 The title of the patent was 1-(Aminoalkyl)-2,3-dihydroimidazo[4,5-b]pyridines. And the patent contained the following:

About 15 title compounds (I; R = cyclohexyl, PhCH2, Ph, p-FC6H4, etc.; R1 = MeN, 4-methyl-1-piperazinyl; X = O, S; n = 2,3) were prepared Thus, 2-chloro-3-nitropyridine was treated with PhNH2 and the product hydrogenated (PdC ) to give 3-amino-2-(phenylamino) pyridine, which was treated with 1,1′-carbonyldiimidazole to give 2-oxo-3-phenyl-2,3- dihydroimidazo[4,5-b]pyridine followed by treatment with Me2NCH2- CH2Cl to give I (R = Ph, R1 = Me2N, X = O, n = 2) isolated as the dicyclohexylsulfamate salt. I were intidepressant at 2.5-100 mg/kg/day in higher animals. The experimental process involved the reaction of 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one(cas: 41010-50-8).Product Details of 41010-50-8

The Article related to imidazopyridine aminopropyl phenyl antidepressant, antidepressant aminopropylimidazopyridine, pyridine nitro chloro aniline addition, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Product Details of 41010-50-8

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On December 16, 1976, Clark, Robert Long; Pessolano, Arsenio A.; Shen, Tsung-Ying published a patent.HPLC of Formula: 41010-50-8 The title of the patent was 1,3-Dihydroimidazo[4,5-b]pyridin-2-ones and thiones. And the patent contained the following:

Imidazopyridinones and thiones I [R = e.g. H, Pr, H2C:CHCH2, Me, PhCH2; R1 = e.g. Ph, 2,4-(MeO)2C6H3, 2,4-Me2C6H3, 3,4-(OCH2O)C6H3, 2-BrC6H4, 3-FC6H4, 2-methyl-6-pyridinyl, 1,3-dihydro-5-isobenzofuranyl; R2 = e.g. H, 6-Me, 6-NO2, 6-NH2; X = O, S], useful as analgesics, antipyretics and inflammation inhibitors (no data), are prepared by reaction of 2-chloro-3-nitropyridine (II) with an aniline, reduction of the resulting 2-anilino-3-nitropyridine to the 3-amino-2-anilinopyridine and cyclocondensation with COCl2 or CSCl2, for example. Thus, reaction of II with 3,4-methylenedioxyaniline gives 2-[3,4-(methylenedioxy)anilino]-3-nitropyridine, which is reduced and cyclocondensed with COCl2 to give I [R = R2 = H, R1 = 3,4-(OCH2O)C6H3, X = O]. The experimental process involved the reaction of 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one(cas: 41010-50-8).HPLC of Formula: 41010-50-8

The Article related to imidazopyridinone, imidazopyridinethione, analgesic imidazopyridinone, antipyretic imidazopyridinone, antiinflammatory imidazopyridinone, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.HPLC of Formula: 41010-50-8

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On October 5, 2018, Nishiguchi, Shigenobu; Izumi, Takuhiro; Kouno, Takayoshi; Sukegawa, Junpei; Ilies, Laurean; Nakamura, Eiichi published an article.Related Products of 73590-85-9 The title of the article was Synthesis of Esomeprazole and Related Proton Pump Inhibitors through Iron-Catalyzed Enantioselective Sulfoxidation. And the article contained the following:

We report here an application of iron catalysis for the kilogram scale asym. synthesis of a proton pump inhibitor, esomeprazole, in 87% yield and 99.4% ee by catalytic sulfoxidation with hydrogen peroxide using an iron salt/chiral Schiff base in combination with a carboxylate salt. Under similar reaction conditions, other proton pump inhibitors such as (S)-lansoprazole, (S)-rabeprazole, and (S)-pantoprazole, were also synthesized in high yield and ee. A carboxylate additive was crucial for the success of this reaction, and we consider that it coordinates to the active iron species, and it also acts as a hydrogen-bond acceptor to coordinate to the substrate through the imidazole NH. The experimental process involved the reaction of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole(cas: 73590-85-9).Related Products of 73590-85-9

The Article related to iron catalyzed enantioselective sulfoxidation esomeprazole synthesis, proton pump inhibitor synthesis iron catalyzed enantioselective sulfoxidation, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Related Products of 73590-85-9

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On April 15, 2012, Che, Guoyong; Xiang, Jing; Tian, Tian; Huang, Qingfei; Cun, Linfeng; Liao, Jian; Wang, Qiwei; Zhu, Jin; Deng, Jingen published an article.Safety of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole The title of the article was Catalytic asymmetric oxidation of 1H-benzimidazolyl pyridinylmethyl sulfides with cumene hydroperoxide catalyzed by a titanium complex with (S,S)-N,N’-dibenzyl tartramide ligand. And the article contained the following:

A chiral titanium complex, formed in situ from Ti(Oi-Pr)4, (S,S)-N,N’-dibenzyl tartramide, and water was found to serve as an efficient catalyst for the asym. oxidations of 1H-benzimidazolyl pyridinylmethyl sulfides with cumene hydroperoxide (CHP) in the absence of a base. Several proton pump inhibitors (PPIs), such as esomeprazole, lansoprazole, rabeprazole, and pantoprazole were obtained in high yield (up to 92%) and excellent enantiomeric excess (up to 96%). The experimental process involved the reaction of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole(cas: 73590-85-9).Safety of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole

The Article related to asym oxidation benzimidazolyl pyridinylmethyl sulfide titanium tartramide catalyst, esomeprazole lansoprazole rabeprazole pantoprazole asym synthesis, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Safety of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On November 21, 2019, Yang, Wenjin; Chang, Kai-Wei; Liu, Suying; Tsai, Cheng-Han published a patent.Reference of 5-Bromo-1H-imidazole-4-carbaldehyde The title of the patent was Preparation of imidazolidines as matrix metalloproteinase (MMP) inhibitors useful in treatment of diseases. And the patent contained the following:

The invention relates to preparation of hydantoin-based compounds (I) useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Compounds I wherein ring B is (un)substituted aryl or heteroaryl; ring C is aryl or heteroaryl; ring D is aryl or heteroaryl; each X, Y, and Z each independently is O, CH2, NH, etc.; R1 is H or alkyl; R2 is H, halo, OH, etc.; R3 is H, halo, alkyl, etc.; R4 is H or alkyl; R5 is H; m is 1-4; n is 1-5, are claimed. The example compound II was prepared by a synthetic procedure from the intermediate compound(also prepared) (procedure given). Compounds I were evaluated for their biol. activities including selective MMP inhibiting activity (data given). Compounds I and related compositions are selective inhibitors of MMP-12 and can be used in treatment of diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis. The experimental process involved the reaction of 5-Bromo-1H-imidazole-4-carbaldehyde(cas: 50743-01-6).Reference of 5-Bromo-1H-imidazole-4-carbaldehyde

The Article related to imidazolidine preparation selective mmp inhibitor disease treatment, hydantoin preparation selective macrophage elastase mmp12 inhibitor disease treatment, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Reference of 5-Bromo-1H-imidazole-4-carbaldehyde

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On February 28, 1979, Svertilova, I. A.; Yutilov, Yu M. published an article.Recommanded Product: 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one The title of the article was Condensed imidazolones. And the article contained the following:

Eight imidazolones I (X, Y = CH, N; R = H, Me, Ph, benzyl; R1 = H, Me, Et, Ph, benzyl) were prepared in 90-9% yield by cyclocondensation of diamines II with (EtO2C)2O. The experimental process involved the reaction of 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one(cas: 41010-50-8).Recommanded Product: 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one

The Article related to cyclocondensation pyrocarbonate pyridinediamine, phenylenediamine pyrocarbonate cyclocondensation, imidazolone condensed, benzimidazolone, imidazopyridinone, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Recommanded Product: 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem